Beta Bionics (NASDAQ:BBNX) Price Target Raised to $20.00 at Bank of America

Key Points

• Bank of America raised Beta Bionics’ price target from $18 to $20 while maintaining a neutral rating, implying roughly 4.28% upside from the prior close. Analysts overall have a “Moderate Buy” consensus with an average target of $21.90.
• BBNX shares rose to $19.18, while the company reported quarterly revenue of $32.01 million and an adjusted loss of $0.53 per share, beating the consensus loss estimate of $0.62.
• Beta Bionics received FDA clearance for its Mint insulin patch pump and plans to integrate Senseonics’ Eversense 365 monitor with its iLet system, but lower 2026 revenue guidance and a securities lawsuit create additional execution and legal risks.

Beta Bionics (NASDAQ:BBNX - Get Free Report) had its target price hoisted by analysts at Bank of America from $18.00 to $20.00 in a research note issued on Tuesday, Benzinga reports. The brokerage presently has a "neutral" rating on the stock. Bank of America's price objective would indicate a potential upside of 4.28% from the stock's previous close.

A number of other research analysts also recently weighed in on BBNX. Weiss Ratings upgraded shares of Beta Bionics from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Tuesday, August 18th. Truist Financial restated a "buy" rating and issued a $23.00 price target (up from $22.00) on shares of Beta Bionics in a research note on Tuesday. Robert W. Baird raised their target price on Beta Bionics from $14.00 to $16.00 and gave the stock a "neutral" rating in a research report on Tuesday. The Goldman Sachs Group upped their price target on shares of Beta Bionics from $17.00 to $19.00 and gave the company a "buy" rating in a research report on Wednesday, July 15th. Finally, Leerink Partners upped their target price on shares of Beta Bionics from $24.00 to $27.00 and gave the company an "outperform" rating in a report on Monday. Seven equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $21.90.

Beta Bionics Stock Performance

Shares of BBNX stock traded up $2.45 during mid-day trading on Tuesday, hitting $19.18. The company's stock had a trading volume of 886,469 shares, compared to its average volume of 1,143,133. Beta Bionics has a 52-week low of $8.80 and a 52-week high of $32.71. The business has a 50-day moving average price of $17.30 and a 200 day moving average price of $13.82. The stock has a market cap of $862.91 million, a price-to-earnings ratio of -11.53 and a beta of 3.37.

Beta Bionics (NASDAQ:BBNX - Get Free Report) last released its quarterly earnings data on Wednesday, July 29th. The company reported ($0.53) EPS for the quarter, beating the consensus estimate of ($0.62) by $0.09. Beta Bionics had a negative return on equity of 26.30% and a negative net margin of 61.31%.The company had revenue of $32.01 million for the quarter. Equities research analysts predict that Beta Bionics will post -2.1 EPS for the current fiscal year.

Insider Transactions at Beta Bionics

In other news, insider Mike Mensinger sold 4,375 shares of Beta Bionics stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $19.11, for a total transaction of $83,606.25. Following the completion of the transaction, the insider directly owned 180,040 shares of the company's stock, valued at $3,440,564.40. The trade was a 2.37% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Steven Russell sold 4,221 shares of Beta Bionics stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $19.11, for a total transaction of $80,663.31. Following the transaction, the insider directly owned 169,628 shares in the company, valued at $3,241,591.08. This trade represents a 2.43% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders have sold 70,132 shares of company stock valued at $1,284,623. Company insiders own 5.30% of the company's stock.

Institutional Trading of Beta Bionics

Several hedge funds have recently added to or reduced their stakes in BBNX. Squarepoint Ops LLC purchased a new stake in shares of Beta Bionics in the 2nd quarter valued at approximately $2,524,000. Bank of America Corp DE purchased a new position in Beta Bionics in the second quarter valued at $8,566,000. Man Group plc purchased a new position in Beta Bionics in the second quarter valued at $419,000. Legal & General Group Plc acquired a new stake in Beta Bionics in the second quarter valued at $62,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in Beta Bionics in the second quarter valued at $172,000.

Key Stories Impacting Beta Bionics

Here are the key news stories impacting Beta Bionics this week:

• Positive Sentiment: The FDA cleared Beta Bionics’ Mint insulin patch pump, which uses a reusable and disposable design, does not require recharging, supports leading continuous glucose monitors, and can be controlled by smartphone. The product is expected to expand the company’s addressable market, with a potential launch in 2027. Beta Bionics Announces FDA Clearance of Mint
• Positive Sentiment: Beta Bionics and Senseonics announced plans to integrate Senseonics’ year-long Eversense 365 continuous glucose monitor with the iLet Bionic Pancreas, targeting a commercial launch in the fourth quarter of 2026. The partnership could improve product functionality and adoption. Senseonics Announces Partnership with Beta Bionics
• Neutral Sentiment: Robert W. Baird raised its price target from $14 to $16 but maintained a neutral rating. The new target remains below the stock’s referenced price, suggesting the analyst sees limited near-term upside despite the recent recovery.
• Negative Sentiment: Beta Bionics lowered its 2026 revenue guidance, raising concerns about near-term demand, execution, and the pace of commercial growth even as it advances new products. Beta Bionics Lowers 2026 Revenue Guidance
• Negative Sentiment: Several law firms publicized a securities class-action lawsuit covering investors who purchased BBNX shares from July 30, 2025, through February 24, 2026. The allegations include overstated iLet safety, efficacy, and clinical outcomes, as well as claims that more than 18,000 customer complaints were not properly reported or investigated. The lead-plaintiff deadline is November 3, 2026. The allegations have not been proven, but the litigation creates legal, financial, and reputational risk. BBNX Shareholder Alert

Beta Bionics Company Profile

Beta Bionics, Inc is a medical technology company focused on developing automated insulin-delivery systems for people with diabetes. Its principal product is the iLet Bionic Pancreas, an automated insulin-delivery system designed to simplify diabetes management by using continuous glucose monitoring data to adjust insulin dosing with limited user input.

The iLet Bionic Pancreas received clearance from the U.S. Food and Drug Administration in 2023 for use by people with type 1 diabetes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.